Truist Slashes Procept BioRobotics Target to $30, Maintains Buy on Long-Term Growth Outlook

In a move underscoring near-term challenges but affirming long-term conviction, analysts at Truist Securities have sharply lowered their price target on Procept BioRobotics (NASDAQ: PRCT) from $47 to $30. The firm, however, reiterated its Buy rating on the stock, pointing to a compelling growth narrative laid out by the company's management.

The adjustment follows Procept's fourth-quarter results, which fell short of Wall Street's revenue and earnings estimates. Despite the quarterly disappointment, Truist's note to investors highlighted the strategic vision presented during the company's recent Analyst Day. Procept's leadership made a case for achieving a sustainable compound annual growth rate of 25% or greater through 2027.

Key pillars of this growth strategy include deeper penetration into the treatment market for Benign Prostatic Hyperplasia (BPH), a common urological condition. The company is also implementing operational changes designed to increase system utilization at hospital sites and improve overall financial transparency, giving investors clearer insight into the business's progress.

"The reset in price target reflects execution risks and a more conservative near-term model," the Truist analyst wrote. "However, the fundamental growth story around robotic-assisted surgical solutions for BPH remains intact. The Analyst Day provided a credible, multi-year framework for expansion that justifies maintaining a positive rating."

The significant target cut reflects broader market skepticism toward high-growth, pre-profitability medical technology firms in a rising interest rate environment. Yet, Procept's focused niche in robotic surgery for a prevalent condition continues to draw investor attention.

Market Voices: A Split Reaction

Michael R., Portfolio Manager at a Healthcare Fund: "This is a classic 'growth vs. execution' story. The long-term addressable market for BPH robotics is massive, and Procept is a pioneer. The target cut hurts, but the maintained Buy signal tells you the analysts still see the path. It's a volatility buy for patient capital."

David Chen, Retail Investor: "Ouch. A near-40% cut in the price target is brutal, no matter how they sugarcoat it with a Buy rating. It feels like the analysts are trying to have it both ways. 'We were wildly optimistic, now we're less so, but trust us anyway.' I'm losing patience with the 'story over numbers' theme."

Sarah Wilkinson, Medical Technology Analyst: "The strategic shifts toward driving utilization are critical. Success in medtech isn't just about placing systems; it's about ensuring they're used frequently. If Procept can execute on that operational pivot, the financials will follow. The lowered target simply prices in a longer ramp-up period."

This analysis is based on publicly available research and financial disclosures.